• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Allergy Clin Immunol . Severe COVID-19 is associated with hyperactivation of the alternative complement pathway

tetano

Editor, Senior Moderator
J Allergy Clin Immunol


. 2021 Nov 17;S0091-6749(21)01761-9.
doi: 10.1016/j.jaci.2021.11.004. Online ahead of print.
Severe COVID-19 is associated with hyperactivation of the alternative complement pathway


Jeremy Boussier[SUP] 1 [/SUP], Nader Yatim[SUP] 2 [/SUP], Armance Marchal[SUP] 3 [/SUP], Jérôme Hadjadj[SUP] 4 [/SUP], Bruno Charbit[SUP] 5 [/SUP], Carine El Sissy[SUP] 3 [/SUP], Nicolas Carlier[SUP] 6 [/SUP], Frédéric Pène[SUP] 7 [/SUP], Luc Mouthon[SUP] 7 [/SUP], Pierre-Louis Tharaux[SUP] 8 [/SUP], Anne Bergeron[SUP] 9 [/SUP], David M Smadja[SUP] 10 [/SUP], Frédéric Rieux-Laucat[SUP] 11 [/SUP], Darragh Duffy[SUP] 12 [/SUP], Solen Kernéis[SUP] 13 [/SUP], Véronique Frémeaux-Bacchi[SUP] 3 [/SUP], Benjamin Terrier[SUP] 14 [/SUP]



Affiliations

Abstract

Background: Severe coronavirus disease 2019 (COVID-19) is characterized by impaired type I interferon activity and a state of hyperinflammation leading to acute respiratory distress syndrome. The complement system has recently emerged as a key player in triggering and maintaining the inflammatory state, but the role of this molecular cascade in severe COVID-19 is still poorly characterized.
Objective: We aimed at assessing the contribution of complement pathways at both protein and transcriptomic levels.
Methods: To this end, we systematically assessed RNA levels of 28 complement genes in circulating whole blood of COVID-19 patients and healthy controls, including genes of the alternative pathway, for which data remain scarce.
Results: We found differential expression of genes involved in the complement system, yet with various expression patterns: while patients displaying moderate disease had elevated expression of classical pathway genes, severe disease was associated with increased lectin and alternative pathway activation, which correlated with inflammation and coagulopathy markers. Additionally, properdin, a pivotal positive regulator of the alternative pathway, showed high RNA expression but was found at low protein concentrations in severe and critical patients, suggesting its deposition at the sites of complement activation. Notably, low properdin levels were significantly associated with the use of mechanical ventilation (AUC = 0.82, p = 0.002).
Conclusion: This study sheds light on the role of the alternative pathway in severe COVID-19 and provides additional rationale for the testing of drugs inhibiting the alternative pathway of the complement system.

Keywords: : Complement system; COVID-19; SARS-CoV-2; alternative pathway; hemostasis; immunology.
 
Back
Top Bottom